Taro Pharmaceutical Industries Ltd.
TARO
Price:
$42.975
Market Cap:
$1.62B
Taro Pharmaceutical Industries Ltd., a science-based pharmaceutical company, develops, manufactures, and markets prescription and over-the-counter pharmaceutical products in the United States, Canada, Israel, and internationally. The company also develops and manufactures active pharmaceutical ingredients primarily for use in its finished dosage form products. It offers its products for various therapeutic categories comprising allergy, analgesic, antibacterial, antibiotic, anticonvulsant, antiemetic, antifungal, anti-inflammatory, anti-cancer, antiplatelet agent, antipyretic, cardiovascular, CNS, corticosteroid, cosmetic, cough and cold, dermatology, diuretic, endocrine, gastrointestinal, l...[Read more]
Industry
Drug Manufacturers - Specialty & Generic
IPO Date
1982-09-14
Stock Exchange
NYSE
Ticker
TARO
PE Ratio
[30.05]
ROE
[3.05%]
Current Ratio
[3.61]
Dividend Yield
[0%]
Enterprise Value
[1.25B]
Dividend History
The ROE as of December 2024 (TTM) for Taro Pharmaceutical Industries Ltd. (TARO) is 3.05%
According to Taro Pharmaceutical Industries Ltd.’s latest financial reports and current stock price. The company's current ROE is 3.05%. This represents a change of 301.28% compared to the average of 0.76% of the last 4 quarters.
Taro Pharmaceutical Industries Ltd. (TARO) Historical ROE (quarterly & annually)
How has TARO ROE performed in the past?
The mean historical ROE of Taro Pharmaceutical Industries Ltd. over the last ten years is 10.47%. The current 3.05% ROE has changed -70.85% with respect to the historical average. Over the past ten years (40 quarters), TARO's ROE was at its highest in in the September 2014 quarter at 11.97%. The ROE was at its lowest in in the June 2020 quarter at -25.84%.
Average
10.47%
Median
10.59%
Minimum
-23.52%
Maximum
34.30%
Taro Pharmaceutical Industries Ltd. (TARO) ROE by Quarter and Year
Discovering the peaks and valleys of Taro Pharmaceutical Industries Ltd. ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 104.36%
Maximum Annual ROE = 34.30%
Minimum Annual Increase = -302.62%
Minimum Annual ROE = -23.52%
| Year | ROE | Change |
|---|---|---|
| 2024 | 3.00% | 104.36% |
| 2023 | 1.47% | -56.82% |
| 2022 | 3.40% | -114.47% |
| 2021 | -23.52% | -302.62% |
| 2020 | 11.61% | -21.49% |
| 2019 | 14.79% | 54.43% |
| 2018 | 9.58% | -56.62% |
| 2017 | 22.07% | -21.20% |
| 2016 | 28.01% | -18.34% |
| 2015 | 34.30% | -3.34% |
Taro Pharmaceutical Industries Ltd. (TARO) Average ROE
How has TARO ROE performed in the past?
The current ROE of Taro Pharmaceutical Industries Ltd. (TARO) is less than than its 3-year, greater than its 5-year, and less than than its 10-year historical averages
3-year avg
2.63%
5-year avg
-0.81%
10-year avg
10.47%
Taro Pharmaceutical Industries Ltd. (TARO) ROE vs. Peers
How is TARO’s ROE compared to its peers?
Taro Pharmaceutical Industries Ltd.’s ROE is less than Eagle Pharmaceuticals, Inc. (17.39%), greater than ANI Pharmaceuticals, Inc. (-1.60%), less than Phibro Animal Health Corporation (6.59%), greater than Deciphera Pharmaceuticals, Inc. (-52.42%), less than Prestige Consumer Healthcare Inc. (12.35%), less than Amphastar Pharmaceuticals, Inc. (22.92%), greater than Pacira BioSciences, Inc. (-10.70%), less than Collegium Pharmaceutical, Inc. (40.81%), greater than Organogenesis Holdings Inc. (-2.69%), less than Lifecore Biomedical, Inc. (17.23%), greater than RedHill Biopharma Ltd. (-103.24%), greater than Evotec SE (-16.30%), less than Supernus Pharmaceuticals, Inc. (6.26%), less than Dr. Reddy's Laboratories Limited (18.58%), less than PetIQ, Inc. (5.54%),
| Company | ROE | Market cap |
|---|---|---|
| 17.39% | $6.74M | |
| -1.60% | $1.14B | |
| 6.59% | $876.50M | |
| -52.42% | $2.21B | |
| 12.35% | $3.89B | |
| 22.92% | $1.84B | |
| -10.70% | $898.99M | |
| 40.81% | $937.19M | |
| -2.69% | $399.81M | |
| 17.23% | $279.89M | |
| -103.24% | $8.09M | |
| -16.30% | $1.77B | |
| 6.26% | $1.97B | |
| 18.58% | $13.05B | |
| 5.54% | $919.17M |
Build a custom stock screener for Taro Pharmaceutical Industries Ltd. (TARO) and other stocks
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Taro Pharmaceutical Industries Ltd. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
Taro Pharmaceutical Industries Ltd. (TARO) and other stocks custom spreadsheet templates
The easiest way to analyze a company like Taro Pharmaceutical Industries Ltd. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
Frequently asked questions❓
What is the ROE?
How can you use the ROE?
What is Taro Pharmaceutical Industries Ltd.'s ROE?
How is the ROE calculated for Taro Pharmaceutical Industries Ltd. (TARO)?
What is the highest ROE for Taro Pharmaceutical Industries Ltd. (TARO)?
What is the 3-year average ROE for Taro Pharmaceutical Industries Ltd. (TARO)?
What is the 5-year average ROE for Taro Pharmaceutical Industries Ltd. (TARO)?
How does the current ROE for Taro Pharmaceutical Industries Ltd. (TARO) compare to its historical average?